Literature DB >> 11260137

Sphingomyelin trafficking in Chlamydia pneumoniae-infected cells.

K Wolf1, T Hackstadt.   

Abstract

Chlamydia pneumoniae is a bacterial obligate intracellular parasite with a developmental cycle common to all members of the genus Chlamydia. Like other chlamydiae, the developmental cycle of C. pneumoniae occurs entirely within a membrane-bound intracellular vacuole, termed an inclusion, that is non-fusogenic with endosomal or lysosomal compartments. To characterize the vesicular interactions of the C. pneumoniae inclusion, we used a fluorescent analogue of ceramide, (N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-Derythro-sphingosine (C6-NBD-Cer), that has previously been used to characterize the endogenous synthesis and transport of sphingolipids from the Golgi apparatus to Chlamydia trachomatis and Chlamydia psittaci inclusions. Sphingolipids are trafficked to C. pneumoniae inclusions in a time-, temperature- and energy-dependent manner with properties very similar to the delivery of sphingomyelin to C. trachomatis inclusions. These results indicate that interactions of the inclusion with a subset of sphingomyelin-containing exocytic vesicles is a property common to all species of chlamydiae.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260137     DOI: 10.1046/j.1462-5822.2001.00098.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  36 in total

1.  Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Authors:  Kelsi M Sandoz; Steven G Eriksen; Brendan M Jeffrey; Robert J Suchland; Timothy E Putman; Dennis E Hruby; Robert Jordan; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Discovery of catalases in members of the Chlamydiales order.

Authors:  Brigida Rusconi; Gilbert Greub
Journal:  J Bacteriol       Date:  2013-05-31       Impact factor: 3.490

3.  Late endocytic multivesicular bodies intersect the chlamydial inclusion in the absence of CD63.

Authors:  Wandy L Beatty
Journal:  Infect Immun       Date:  2008-04-21       Impact factor: 3.441

4.  The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cells.

Authors:  Kelsi M Sandoz; William G Valiant; Steven G Eriksen; Dennis E Hruby; Robert D Allen; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

5.  Degradation of Chlamydia pneumoniae by peripheral blood monocytic cells.

Authors:  Katerina Wolf; Elizabeth Fischer; Ted Hackstadt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Drosophila melanogaster S2 cells: a model system to study Chlamydia interaction with host cells.

Authors:  C Elwell; J N Engel
Journal:  Cell Microbiol       Date:  2005-05       Impact factor: 3.715

Review 7.  Acquisition of nutrients by Chlamydiae: unique challenges of living in an intracellular compartment.

Authors:  Hector Alex Saka; Raphael H Valdivia
Journal:  Curr Opin Microbiol       Date:  2009-12-16       Impact factor: 7.934

8.  Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis.

Authors:  Shinn-Jong Jiang; Lee Ann Campbell; Mark W Berry; Michael E Rosenfeld; Cho-Chou Kuo
Journal:  Microbes Infect       Date:  2008-07-17       Impact factor: 2.700

9.  Retinoic acid inhibits the infectivity and growth of Chlamydia pneumoniae in epithelial and endothelial cells through different receptors.

Authors:  Mirja Puolakkainen; Amy Lee; Tadayoshi Nosaka; Hideto Fukushi; Cho-Chou Kuo; Lee Ann Campbell
Journal:  Microb Pathog       Date:  2007-11-23       Impact factor: 3.738

10.  Rab GTPases are recruited to chlamydial inclusions in both a species-dependent and species-independent manner.

Authors:  Kimberly A Rzomp; Luella D Scholtes; Benjamin J Briggs; Gary R Whittaker; Marci A Scidmore
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.